Platine, Avastin and OLAparib in 1st Line (PAOLA-1)

Randomized, Double-Blind, Phase III Trial Olaparib vs. Placebo Patients With Advanced FIGO Stage IIIB-IV High Grade Serious or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer Treated Standard First-Line Treatment

Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB - IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance.

Study Overview

• Status: Completed
• Conditions: Ovarian Cancer
• Intervention / Treatment: Drug: Olaparib; Drug: Placebo

Detailed Description

Patients with advanced FIGO stage IIIB - IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance.

• Study Type: Interventional
• Enrollment (Actual): 806
• Phase: Phase 3

Contacts and Locations

Study Locations

• Austria
  • Graz, Austria, 8036
    • Medical University of Graz
  • Graz, Austria, 8020
    • KH der Barmherzigen Brüder Graz
  • Innsbruck, Austria, 6020
    • Medical University of Innsbruck
  • Salzburg, Austria, 5020
    • Landeskrankenhaus Salzburg
  • Vienna, Austria, 1090
    • Medical University of Vienna
  • Vienna, Austria, 1130
    • Krankenhaus Hietzing
• Belgium
  • Bruxelles, Belgium, B1000
    • Institut Jules Bordet
  • Edegem, Belgium, B-2650
    • Antwerp University Hospital
  • Leuven, Belgium, B - 3000
    • Uz Gasthuisberg
  • Liège, Belgium, B-4000
    • Hôpital de la Citadelle
  • Namur, Belgium, B-5000
    • Clinique et Maternité Sainte Elisabeth
  • Yvoir, Belgium, B-5530
    • CHU Dinant Godinne
• Denmark
  • Copenhagen, Denmark, 2100
    • Rigshospitalet
  • Herlev, Denmark, 2720
    • Herlev Hospital
• Finland
  • Kuopio, Finland, 70210
    • Kuopio University Hospital
  • Oulu, Finland, FIN-90029
    • Oulu University Hospital
  • Tampere, Finland, Fi-33521
    • Tampere University Hospital
  • Turku, Finland
    • Turku University Hospital
• France
  • Angers, France, 49100
    • ICO Paul Papin
  • Avignon, France, 84918
    • Institut Sainte-Catherine
  • Besancon, France, 25030
    • Hôpital Jean Minjoz
  • Bordeaux, France, 33076
    • Institut Bergonié
  • Bordeaux, France, 33300
    • Polyclinique Bordeaux Nord
  • Caen, France, 14000
    • Centre Francois Baclesse
  • Clermont-ferrand, France, 63000
    • Centre Jean Perrin
  • Dijon, France, 21079
    • Centre Georges Francois Leclerc
  • Grenoble, France, 38028
    • Groupe Hospitalier Mutualiste de Grenoble
  • La Roche-sur-yon, France, 85925
    • Centre Hospitalier Départemental Les Oudairies
  • La Tronche, France, 38700
    • Hôpital Michallon - Centre Hospitalier Universitaire de Grenoble
  • Le Mans, France, 72000
    • Centre Jean Bernard - Clinique Victor Hugo
  • Lille, France, 59037
    • Centre Hospitalier Régional Universitaire de Lille - Hôpital Huriez
  • Lille, France, 59200
    • Centre Oscar Lambret
  • Lyon, France, 69373
    • Centre Leon Berard
  • Marseille, France, 13009
    • Institut Paoli Calmettes
  • Mont-de-marsan, France, 40024
    • Hôpital de Mont-de-Marsan
  • Montpellier, France, 34298
    • ICM Val D'Aurelle
  • Mougins, France, 06250
    • Centre Azuréen de Cancérologie
  • Nantes, France, 44202
    • Centre Catherine de Sienne - Group confluent
  • Nice, France, 06189
    • Centre Antoine Lacassagne
  • Orleans, France, 45067
    • Centre Hospitalier Regional D'Orleans
  • Paris, France, 75020
    • Hopital Tenon
  • Paris, France, 75014
    • Hopital Cochin
  • Paris, France, 75005
    • Institut Curie - Hopital Claudius Régaud
  • Paris, France, 75012
    • Hôpital des Diaconesses
  • Paris, France, 75674
    • Groupe Hospitalier Saint-Joseph
  • Perigueux, France, 20004
    • Clinique Francheville
  • Pierre-benite, France, 69495
    • Centre Hospitalier Lyon Sud
  • Plérin, France, 22190
    • Centre CARIO - HPCA
  • Poitiers, France, 86021
    • Hôpital de la Milétrie - CHU de Poitiers - Pôle Régional de Cancérologie
  • Rennes, France, 35042
    • Centre Eugene Marquis
  • Rouen, France, 76038
    • Centre Henri Becquerel
  • Saint-cloud, France, 92210
    • Hôpital René Huguenin, Institut Curie
  • Saint-herblain, France, 44805
    • ICO Centre Rene Gauducheau
  • Strasbourg, France, 67065
    • Centre Paul Strauss
  • Strasbourg, France, 67000
    • Centre de Radiothérapie - Clinique Sainte-Anne
  • Strasbourg, France, 67200
    • Hôpitaux Universitaires de Strasbourg
  • Toulouse, France, 31059
    • Institut Claudius Regaud
  • Toulouse, France, 31076
    • Clinique Pasteur - Oncosud
  • Vandoeuvre-les-nancy, France, 54511
    • ICL Institut de Cancérologie de Lorraine
  • Villejuif, France, 94805
    • Institut Gustave Roussy
  • Ilhe De France
    • Paris, Ilhe De France, France, 75015
      • Hopital Europeen Georges Pompidou
• Germany
  • Aschaffenburg, Germany, 63739
    • Klinikum Aschaffenburg
  • Augsburg, Germany, 86156
    • Klinikum Augsburg
  • Bad Homburg, Germany, 61352
    • Hochtaunus-Kliniken
  • Berlin, Germany, 13125
    • Helios Klinikum Berlin-Buch
  • Berlin, Germany, 10367
    • Praxisklinik Krebsheilkunde fur Frauen
  • Berlin, Germany, 13353
    • Charité - Universitätsmedizin Berlin (CVK)
  • Bottrop, Germany, 46236
    • Onkologie Bottrop
  • Bremen, Germany, 28111
    • GYNAEKOLOGICUM Bremen
  • Dessau, Germany, 06847
    • Städtisches Klinikum Dessau
  • Dresden, Germany, 01307
    • Universitätsklinikum Carl Gustav Carus
  • Düsseldorf, Germany, 40225
    • Universitätsklinikum Düsseldorf
  • Düsseldorf, Germany, 40217
    • Evangelisches Krankenhaus Düsseldorf
  • Erlangen, Germany, 91054
    • Universitätsfrauenklinik Erlangen
  • Essen, Germany, 45147
    • Universitatsklinikum Essen
  • Essen, Germany, 45136
    • Kliniken Essen Mitte
  • Esslingen, Germany, 73730
    • Klinikum Esslingen
  • Frankfurt, Germany, 60590
    • Klinikum der Johann Wolfgang Goethe-Universität
  • Frankfurt, Germany, 65929
    • Klinikum Frankfurt Höchst
  • Freiburg, Germany, 79106
    • Universitätsfrauenklinik Freiburg
  • Greifswald, Germany, 17475
    • Universitätsmedizin Greifswald
  • Göttingen, Germany, 37075
    • Universitäts-Frauenklinik Göttingen
  • Gütersloh, Germany, 33332
    • Klinkum Gütersloh
  • Halle, Germany, 06120
    • Universitätsklinikum Halle
  • Hamburg, Germany, 20246
    • Universitätsklinikum Hamburg-Eppendorf
  • Hamburg, Germany, 22457
    • Albertinen Krankenhaus
  • Hannover, Germany, 30625
    • Medizinische Hochschule Hannover
  • Hannover, Germany, 30177
    • Gynakologisch-Onkologische Praxis Hannover
  • Heidelberg, Germany, 69120
    • Universitätsklinikum Heidelberg
  • Jena, Germany, 07743
    • Universitatsklinikum Jena
  • Karlsruhe, Germany, 76135
    • St. Vincentius Kliniken
  • Kassel, Germany, 34125
    • Klinikum Kassel
  • Kiel, Germany, 24105
    • Universitätsklinikum Schleswig-Holstein
  • Konstanz, Germany, 78462
    • Klinikum Konstanz
  • Krefeld, Germany, 47805
    • Helios Klinikum Krefeld
  • Köln, Germany, 50931
    • Universitätsfrauenklinik Köln
  • Köln, Germany, 50935
    • St. Elisabeth Krankenhaus
  • Ludwigsburg, Germany, 71640
    • Klinikum Ludwigsburg
  • Lübeck, Germany, 23538
    • Universitätsklinikum Schleswig-Holstein
  • Marburg, Germany, 35043
    • Universitätsklinikum Giessen und Marburg
  • Minden, Germany, 32429
    • Johannes Wesling Klinikum
  • München, Germany, 81377
    • Klinikum der Universität München
  • München, Germany, 81675
    • Klinikum rechts der Isar
  • Münster, Germany, 48149
    • Universitatsklinikum Munster
  • Neumarkt, Germany, 92318
    • Kliniken des Landkreises Neumarkt
  • Offenbach, Germany, 63069
    • Sana Klinikum Offenbach
  • Offenburg, Germany, 77654
    • Ortenau Klinikum
  • Ravensburg, Germany, 88212
    • Onkologie Ravensburg
  • Regensburg, Germany, 93053
    • Universitätsfrauenklinik Regensburg
  • Reutlingen, Germany, 72764
    • Klinikum am Steinenberg
  • Rosenheim, Germany, 83022
    • RoMed Klinikum Rosenheim
  • Rostock, Germany, 18059
    • Klinikum Südstadt
  • Stuttgart, Germany, 70376
    • Robert-Bosch-Krankenhaus
  • Tübingen, Germany, 72076
    • Universitats-Frauenklinik Tubingen
  • Ulm, Germany, 89075
    • Universitatsklinikum Ulm
  • Wiesbaden, Germany, 65199
    • Helios Dr. Horst Schmidt Kliniken
  • Witten, Germany, 58452
    • Marien Hospital Witten
  • Wolfsburg, Germany, 38440
    • amO Wolfsburg
  • Worms, Germany, 67550
    • Klinikum Worms
  • Würzburg, Germany, 97080
    • Universitatsklinikum Wurzburg
• Italy
  • Aviano, Italy, 33081
    • Centro Riferimento Oncologico
  • Bologna, Italy, 40138
    • Policlinico S.Orsola-Malpighi
  • Brescia, Italy, 25120
    • Spedali Civili-Università di Brescia
  • Brindisi, Italy, 72100
    • Ospedale Senatore Antonio Perrino
  • Genova, Italy, 16128
    • EO Ospedali Galliera
  • Lucca, Italy, 55100
    • Ospedale San Luca
  • Milano, Italy, 20141
    • Istituto Europeo di Oncologia
  • Milano, Italy, 20133
    • Istituto Nazionale Tumori
  • Napoli, Italy, 80131
    • Istituto Nazionale Tumori - IRCCS Pascale
  • Padova, Italy, 35128
    • Istituto Oncologico Veneto
  • Perugia, Italy, 06122
    • Ospedale Santa Maria della Misericordia
  • Pisa, Italy, 56124
    • Ospedale Santa Chiara
  • Prato, Italy, 59100
    • AO ASL 4 - Ospedale di Prato
  • Reggio Emilia, Italy, 42100
    • Arcispedale S. M. Nuova
  • Roma, Italy, 00144
    • Istituto Regina Elena
  • Roma, Italy, 00161
    • Policlinico Umberto I La Sapienza
  • Roma, Italy, 00168
    • Policlinico Universitario Gemelli Università Cattolica del Sacro Cuore
  • Torino, Italy, 10126
    • Ospedale S. Anna
  • Torino, Italy, 10128
    • Ospedale Mauriziano
  • Trento, Italy, 38100
    • Ospedale Santa Chiara
• Japan
  • Ehime, Japan, 791-0204
    • Ehime University Hospital
  • Hyogo, Japan, 673-0021
    • Hyogo Cancer Center
  • Ibaraki, Japan, 305-0005
    • University of Tsukuba Hospital
  • Kagoshima, Japan, 890-8520
    • Kagoshima University Medical and Dental Hospital
  • Saitama, Japan, 350-1298
    • Saitama Medical University International Medical Center
  • Tochigi, Japan, 329-0498
    • Jichi Medical University Hospital
  • Tokyo, Japan, 104-0045
    • National Cancer Center Hospital
• Monaco
  • Monaco, Monaco, 98000
    • Centre Hospitalier Princesse Grace
• Spain
  • Alcorcón, Spain, 28922
    • H. U. Fundación Alcorcón
  • Barcelona, Spain, 8026
    • H. de la Santa Creu i Sant Pau
  • Barcelona, Spain, 8208
    • C.S. Parc Tauli
  • Córdoba, Spain, 14004
    • H. U. Reina Sofía
  • Lleida, Spain, 25198
    • H.U. Arnau de Vilanova
  • Madrid, Spain, 28033
    • MD Anderson Cancer Center Madrid
  • Madrid, Spain, 28034
    • H. U. Ramón y Cajal
  • Madrid, Spain, 28041
    • H. U. 12 de Octubre
  • Oviedo, Spain, 33011
    • H.U. Central de Asturias
  • Pamplona, Spain, 31008
    • Complejo Hospitalario de Navarra
  • Valencia, Spain, 46014
    • H. General Universitario de Valencia
  • Valencia, Spain, 46026
    • H. U. P. La Fe
  • València, Spain, 46009
    • Instituto Valenciano de Oncologia
  • Zaragoza, Spain, 50009
    • H. U. Miguel Servet
• Sweden
  • Linköping, Sweden, 58185
    • Linköping University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

I-1. Female Patient must be ≥18 years of age. I-2. Signed informed consent and ability to comply with treatment and follow-up.

I-3. Patient with newly diagnosed I-3-1 Ovarian cancer, primary peritoneal cancer and/or fallopian-tube cancer,

I-3-2 Histologically confirmed (based on local histopathological findings):

• high grade serous or
• high grade endometrioid or
• other epithelial non mucinous ovarian cancer in a patient with germline BRCA 1 or 2 deleterious mutation I-3-3 at an advanced stage: FIGO stage IIIB, IIIC, or IV of the 1988 FIGO classification.

I-4. Patient who has completed prior to randomization first line platinum-taxane chemotherapy:

1. Platinum-taxane based regimen must have consisted of a minimum of 6 treatment cycles and a maximum of 9. However if platinum based therapy must be discontinued early as a result of non hematological toxicity specifically related to the platinum regimen, (i.e. neurotoxicity, hypersensitivity etc.), patient must have received a minimum of 4 cycles of the platinum regimen.
2. Intravenous, intraperitoneal, or neoadjuvant platinum based chemotherapy is allowed; for weekly therapy, three weeks are considered one cycle. Interval debulking is allowed.

I-5. Patient must have received prior to randomization a minimum of 3 cycles of bevacizumab in combination with the 3 last cycles of platinum-based chemotherapy. Only in case of interval debulking surgery, it is allowed to realize only 2 cycles of bevacizumab in combination with the last 3 cycles of platinium-based chemotherapy. Bevacizumab treatment should be administered at a dose 15mg/kg q3 weeks up to a total of 15 months.

I-6. Patient must be prior to randomization without evidence of disease (NED) or in complete response (CR) or partial response (PR) from her first line treatment. There should be no clinical evidence of disease progression (physical exam, imagery, CA 125) throughout her first line treatment and prior to study randomization.

I-7. Patient must be randomized at least 3 weeks and no more than 9 weeks after her last dose of chemotherapy (last dose is the day of the last infusion) and all major toxicities from the previous chemotherapy must have resolved to CTC AE grade 1 or better (except alopecia and peripheral neuropathy).

I-8. Patient must have normal organ and bone marrow function:

1. Hemoglobin ≥ 10.0 g/dL.
2. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L.
3. Platelet count ≥ 100 x 109/L.
4. Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN).
5. Aspartate aminotransferase /Serum Glutamic Oxaloacetic Transaminase (ASAT/SGOT)) and Alanine aminotransferase /Serum Glutamic Pyruvate Transaminase (ALAT/SGPT)) ≤ 2.5 x ULN, unless liver metastases are present in which case they must be ≤ 5 x ULN.
6. Serum creatinine ≤ 1.25 x institutional ULN and creatinine clearance > 50 mL/min.

7. Patient not receiving anticoagulant medication who has an International Normalized Ratio (INR) ≤1.5 and an Activated ProThrombin Time (aPTT) ≤1.5 x ULN.

   The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or APTT is within therapeutic limits (according to site medical standard). If the patient is on oral anticoagulants, dose has to be stable for at least two weeks at the time of randomization.

8. Urine dipstick for proteinuria < 2+. If urine dipstick i s ≥2+, 24-hour urine must demonstrate <1 g of protein in 24 hours.
9. Normal blood pressure or adequately treated and controlled hypertension (systolic BP ≤ 140 mmHg and/or diastolic BP ≤ 90 mmHg).

I-9. Eastern Cooperative Oncology Group (ECOG) performance status 0-1. I-10. Formalin fixed, paraffin embedded (FFPE) tumor sample from the primary cancer must be available for central BRCA testing and test result must be available for stratification.

I-11. Postmenopausal or evidence of non-childbearing status for women of childbearing potential prior to the first dose of study treatment. (see appendix 4) I-12. For France only: In France, a subject will be eligible for randomization in this study only if either affiliated to, or a beneficiary of, a social security category.

Exclusion Criteria:

E-1. Non-epithelial origin of the ovary, the fallopian tube or the peritoneum (i.e. germ cell tumors).

E-2. Ovarian tumors of low malignant potential (e.g. borderline tumors), or mucinous carcinoma.

E-3. Patient with synchronous primary endometrial cancer unless both of the following criteria are met:

1. stage < II,
2. Less than 60 years old at the time of diagnosis of endometrial cancer with stage IA or IB grade 1 or 2, or stage IA grade III endometrioid adenocarcinoma OR ≥ 60 years old at the time of diagnosis of endometrial cancer with stage IA grade 1 or 2 endometrioid adenocarcinoma.

Patient with serous or clear cell adenocarcinoma or carcinosarcoma of the endometrium is not eligible.

E-4. Other malignancy within the last 5 years except: adequately treated non-melanoma skin cancer curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS). Patient with a history of localized malignancy diagnosed over 5 years ago may be eligible provided she completed her adjuvant systemic therapy prior to randomization and that the patient remains free of recurrent or metastatic disease.

Patient with history of primary triple negative breast cancer may be eligible provided she completed her definitive anticancer treatment more than 3 years ago and she remains breast cancer disease free prior to start of study treatment.

E-5. Patient with myelodysplastic syndrome/acute myeloid leukemia history E-6. Patient having experienced for at least one cycle, a delay > 2 weeks due to prolonged hematological recovery during the first line chemotherapy E-7. Patient receiving radiotherapy within 6 weeks prior to study treatment E-8. Major surgery within 4 weeks of starting study treatment and patient must have recovered from any effects of any major surgery E-9. Previous allergenic bone marrow transplant. E-10. Any previous treatment with PARP inhibitor, including olaparib. E-11. Administration of other simultaneous chemotherapy drugs, any other anticancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period (hormonal replacement therapy is permitted as are steroidal antiemetics).

E-12. Current or recent (within 10 days prior to randomization) chronic use of aspirin > 325 mg/day.

E-13. Concomitant use of known potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir.

E-14. Prior history of hypertensive crisis (CTC-AE grade 4) or hypertensive encephalopathy.

E-15. Clinically significant (e.g. active) cardiovascular disease, including:

1. Myocardial infarction or unstable angina within ≤ 6 months of randomization,
2. New York Heart Association (NYHA) ≥ grade 2congestive heart failure (CHF).
3. Poorly controlled cardiac arrhythmia despite medication (patient with rate controlled atrial fibrillation are eligible), or any clinically significant abnormal finding on resting ECG,
4. Peripheral vascular disease grade ≥ 3 (e.g. symptomatic and interfering with activities of daily living [ADL] requiring repair or revision).

E-16. Previous Cerebro-Vascular Accident (CVA), Transient Ischemic Attack (TIA) or Sub- Arachnoids Hemorrhage (SAH) within 6 months prior to randomization.

E-17. History or evidence of hemorrhagic disorders within 6 months prior to randomization.

E-18. Evidence of bleeding diathesis or significant coagulopathy (in the absence of coagulation).

E-19. History or clinical suspicion of brain metastases or spinal cord compression. CT/MRI of the brain is mandatory (within 4 weeks prior to randomization) in case of suspected brain metastases. Spinal MRI is mandatory (within 4 weeks prior to randomization) in case of suspected spinal cord compression.

E-20. History or evidence upon neurological examination of central nervous system (CNS) disease, unless adequately treated with standard medical therapy (e.g. uncontrolled seizures).

E-21. Significant traumatic injury during 4 weeks prior to randomization. E-22. Non-healing wound, active ulcer or bone fracture. Patient with granulating incisions healing by secondary intention with no evidence of facial dehiscence or infection is eligible but require 3 weekly wound examinations.

E-23. History of VEGF therapy related abdominal fistula or gastrointestinal perforation or active gastrointestinal bleeding within 6 months prior to the first study treatment.

E-24. Current, clinically relevant bowel obstruction, including sub-occlusive disease, related to underlying disease.

E-25. Patient with evidence of abdominal free air not explained by paracentesis or recent surgical procedure.

E-26. Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment related complications.

E-27. Pregnant or lactating women. E-28. Participation in another clinical study with an investigational product during her chemotherapy course immediately prior to randomization.

E-29. Patient unable to swallow orally administered medication and patient with gastrointestinal disorders likely to interfere with absorption of the study medication.

E-30. Patient with a known hypersensitivity to olaparib or any of the recipients of the product.

E-31. Immunocompromised patient, e.g., with known active hepatitis (i.e. Hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids or patient who is known to be serologically positive for human immunodeficiency virus (HIV).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Olaparib; Tablets per os 300 mg	Drug: Olaparib; Tablets, per os, 300 mg twice daily;
Placebo Comparator: Placebo; Tablets per os 300 mg	Drug: Placebo; Tablets, per os, 300 mg twice daily.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Efficacy by progression free survival (PFS1)	phase up to a total of 15 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival	Overall survival is defined as the time from the date of randomization until death due to any cause.	Study end
Time to earliest progression by RECIST or CA-125	Time to earliest progression by RECIST v. 1.1 or CA-125 or death is defined as the time from randomization to the earliest date of RECIST or CA-125 progression or death by any cause.	Study end
Second Progression Free Survival (PFS2)	Time from randomization to second progression is defined as the time from the date of randomization to the earliest of the progression event subsequent to that used for the primary variable PFS, or date of death.	Study end
Time to start of first subsequent therapy or death (TFST)	Time to start of first subsequent therapy or death (TFST) will be assessed. TFST is defined as the time from the date of randomization to the earliest of the date of anti-cancer therapy start date following study treatment discontinuation, or death.	Study end
Time to start of second subsequent therapy or death (TSST)	Time to start of second subsequent therapy or death (TSST) will be assessed. TSST is defined as the time from the date of randomization to the earliest of the date of second subsequent anti-cancer therapy start date following study treatment discontinuation, or death.	Study end
Safety and Tolerability		Study end
Patient reported outcome		2 years after last patient included

Collaborators and Investigators

• Sponsor: Arcagy Research
• Collaborators: Belgian Gynaecological Oncology Group; Grupo Español de Investigación en Cáncer de Ovario; Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies; Mario Negri Gynecologic Oncology group (MaNGO); Nordic Society of Gynaecological Oncology - Clinical Trials Unit; Arbeitsgemeinschaft Gynaekologische Onkologie Austria; Arbeitsgemeinschaft Gynaekologishe Onkologie Germany; Gynecologic Oncology Trial & Investigation Consortium
• Investigators: Principal Investigator: Isabelle RAY COQUARD, MD, PhD, Centre Leon Berard

Publications and helpful links

General Publications

• Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, Fujiwara K, Vergote I, Colombo N, Maenpaa J, Selle F, Sehouli J, Lorusso D, Guerra Alia EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marme F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361.
• Gonzalez-Martin A, Desauw C, Heitz F, Cropet C, Gargiulo P, Berger R, Ochi H, Vergote I, Colombo N, Mirza MR, Tazi Y, Canzler U, Zamagni C, Guerra-Alia EM, Levache CB, Marme F, Bazan F, de Gregorio N, Dohollou N, Fasching PA, Scambia G, Rubio-Perez MJ, Milenkova T, Costan C, Pautier P, Ray-Coquard I; PAOLA1/ENGOT-ov25 investigators. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial. Eur J Cancer. 2022 Oct;174:221-231. doi: 10.1016/j.ejca.2022.07.022. Epub 2022 Sep 5.
• Fujiwara K, Fujiwara H, Yoshida H, Satoh T, Yonemori K, Nagao S, Matsumoto T, Kobayashi H, Bourgeois H, Harter P, Mosconi AM, Vazquez IP, Reinthaller A, Fujita T, Rowe P, Pujade-Lauraine E, Ray-Coquard I. Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial. J Gynecol Oncol. 2021 Sep;32(5):e82. doi: 10.3802/jgo.2021.32.e82.

Helpful Links

• Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Study record dates

Study Major Dates

• Study Start (Actual): May 6, 2015
• Primary Completion (Actual): March 22, 2019
• Study Completion (Actual): March 22, 2022

Study Registration Dates

• First Submitted: June 18, 2015
• First Submitted That Met QC Criteria: June 22, 2015
• First Posted (Estimate): June 23, 2015

Study Record Updates

• Last Update Posted (Actual): August 2, 2022
• Last Update Submitted That Met QC Criteria: August 1, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Keywords: olaparib; bevacizumab; placebo; Advanced FIGO IIIB; IV high grade serious ovarian cancer; endometrioid ovarian cancer; standard first-line treatment; platinum-taxane chemotherapy
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Carcinoma; Neoplasms, Glandular and Epithelial; Genital Neoplasms, Female; Endocrine System Diseases; Ovarian Diseases; Adnexal Diseases; Gonadal Disorders; Endocrine Gland Neoplasms; Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Poly(ADP-ribose) Polymerase Inhibitors; Olaparib
• Other Study ID Numbers: GINECO-OV125b